ATE386730T1 - Phenylpiperazinderivate als serotonin wiederaufnahmehemmer - Google Patents

Phenylpiperazinderivate als serotonin wiederaufnahmehemmer

Info

Publication number
ATE386730T1
ATE386730T1 AT02800051T AT02800051T ATE386730T1 AT E386730 T1 ATE386730 T1 AT E386730T1 AT 02800051 T AT02800051 T AT 02800051T AT 02800051 T AT02800051 T AT 02800051T AT E386730 T1 ATE386730 T1 AT E386730T1
Authority
AT
Austria
Prior art keywords
reuppost
serotonin
inhibitors
phenylpiperazine derivatives
phenylpiperazine
Prior art date
Application number
AT02800051T
Other languages
German (de)
English (en)
Inventor
Thomas Ruhland
Garrick Smith
Benny Bang-Andersen
Ask Pueschl
Ejner Knud Moltzen
Kim Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE386730(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE386730T1 publication Critical patent/ATE386730T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT02800051T 2001-10-04 2002-10-02 Phenylpiperazinderivate als serotonin wiederaufnahmehemmer ATE386730T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04

Publications (1)

Publication Number Publication Date
ATE386730T1 true ATE386730T1 (de) 2008-03-15

Family

ID=8160750

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06016609T ATE441631T1 (de) 2001-10-04 2002-10-02 Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
AT02800051T ATE386730T1 (de) 2001-10-04 2002-10-02 Phenylpiperazinderivate als serotonin wiederaufnahmehemmer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06016609T ATE441631T1 (de) 2001-10-04 2002-10-02 Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer

Country Status (38)

Country Link
US (10) US7144884B2 (enEXAMPLES)
EP (2) EP1436271B3 (enEXAMPLES)
JP (3) JP3896116B2 (enEXAMPLES)
KR (3) KR100770194B1 (enEXAMPLES)
CN (1) CN1319958C (enEXAMPLES)
AR (2) AR036659A1 (enEXAMPLES)
AT (2) ATE441631T1 (enEXAMPLES)
AU (2) AU2002333220C1 (enEXAMPLES)
BE (1) BE2014C036I2 (enEXAMPLES)
BR (3) BR122012023120B8 (enEXAMPLES)
CA (1) CA2462110C (enEXAMPLES)
CO (1) CO5580746A2 (enEXAMPLES)
CY (3) CY1107924T1 (enEXAMPLES)
DE (2) DE60233608D1 (enEXAMPLES)
DK (2) DK1436271T6 (enEXAMPLES)
EA (2) EA011096B1 (enEXAMPLES)
EG (1) EG25095A (enEXAMPLES)
ES (2) ES2298425T7 (enEXAMPLES)
FR (1) FR14C0033I2 (enEXAMPLES)
HR (1) HRP20040220A2 (enEXAMPLES)
HU (3) HU228956B1 (enEXAMPLES)
IL (1) IL160655A0 (enEXAMPLES)
IS (2) IS2578B (enEXAMPLES)
LT (1) LTC1436271I2 (enEXAMPLES)
LU (1) LU92397I2 (enEXAMPLES)
ME (1) ME00039B (enEXAMPLES)
MX (1) MXPA04002959A (enEXAMPLES)
MY (1) MY140950A (enEXAMPLES)
NL (1) NL300652I2 (enEXAMPLES)
NO (3) NO326443B1 (enEXAMPLES)
NZ (1) NZ531556A (enEXAMPLES)
PL (2) PL209253B1 (enEXAMPLES)
PT (2) PT1749818E (enEXAMPLES)
RS (2) RS52326B (enEXAMPLES)
SI (1) SI1436271T1 (enEXAMPLES)
UA (2) UA81749C2 (enEXAMPLES)
WO (1) WO2003029232A1 (enEXAMPLES)
ZA (1) ZA200401583B (enEXAMPLES)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
EA009417B1 (ru) * 2003-04-04 2007-12-28 Х. Лундбекк А/С Производные 4-(2-фенилоксифенил)пиперидина или -1,2,3,6-тетрагидропиридина в качестве ингибиторов обратного захвата серотонина
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
ES2309514T3 (es) 2003-04-04 2008-12-16 H. Lundbeck A/S Derivados de 4-(2-fenilsufanil-fenil)-piperidina como inhibidores de la recaptacion de serotonina.
BRPI0408647A (pt) * 2003-04-04 2006-03-07 Lundbeck & Co As H composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
PT1635828E (pt) * 2003-04-04 2008-07-01 Lundbeck & Co As H Derivados de 4-(2-feniloxifenil) piperidina ou de 1,2,3,6-tetrahidropiridina como inibidores da recaptação da serotonina
MXPA06007172A (es) 2003-12-23 2006-08-23 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-bencilamina como ssri.
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7923444B2 (en) 2005-02-10 2011-04-12 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
BRPI0712758A2 (pt) * 2006-06-16 2012-09-25 H Lundbeck & Co As composto e sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, método de tratamento de uma doença. e, uso do compsoto
DK2044043T4 (da) * 2006-06-16 2021-04-12 H Lundbeck As 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazinhydrobromid som en forbindelse med kombineret serotoningenoptag, 5-ht3 og 5-ht1a-aktivitet til behandling af kognitiv svækkelse
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
AU2007260356B2 (en) 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
UA95801C2 (ru) * 2006-06-16 2011-09-12 Х. Луннбек А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)-фенил]пиперидина с комбинированным ингибированием обратного захвата серотонина и норэпинефрина для лечения невропатической боли
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
TWI461407B (zh) 2008-11-14 2014-11-21 Theravance Biopharma R & D Ip Llc 製備４－〔２－（２－氟苯氧基甲基）苯基〕哌啶化合物之方法
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
NZ596431A (en) * 2009-04-24 2012-12-21 Lundbeck & Co As H Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
PT2470166E (pt) * 2009-08-24 2013-10-02 Lundbeck & Co As H Novas composições de 1-[2-(2,4-dimetil-fenilsulfanil)- fenil]piperazina
US8846655B2 (en) * 2009-10-30 2014-09-30 Janssen Pharmaceutica, Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
KR20130060220A (ko) 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
CN102970982B (zh) 2010-04-30 2015-01-14 武田药品工业株式会社 肠溶片剂
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
GEP201706655B (en) 2011-06-20 2017-04-25 H Lundbeck As Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
AU2012340015B2 (en) 2011-11-14 2017-09-21 Alfasigma S.P.A. Assays for selecting a treatment regimen for a subject with depression and methods for treatment
PL2800746T3 (pl) 2012-01-03 2019-07-31 H. Lundbeck A/S Sposób wytwarzania 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
CA2885266C (en) 2012-09-19 2020-05-12 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
US9211288B2 (en) 2012-12-13 2015-12-15 H. Lundbeck A/S Compositions comprising vortioxetine and donepezil
AP2015008640A0 (en) * 2013-02-22 2015-08-31 Lundbeck & Co As H Vortioxetine manufacturing process
ES2724246T3 (es) * 2013-04-04 2019-09-09 Lek Pharmaceuticals Nuevo proceso para la síntesis de 1-(2-((2,4-dimetilfenil)tio)fenil)piperazina
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
WO2015044963A1 (en) 2013-09-30 2015-04-02 Cadila Healthcare Limited An amorphous vortioxetine and salts thereof
EP2878596A1 (en) 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
RU2679661C1 (ru) 2013-12-20 2019-02-12 Х. Лундбекк А/С Применение антагониста опиоидных рецепторов с k-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками
EP2894154A1 (en) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN106103418A (zh) 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
EP3023417B1 (en) 2014-11-21 2017-06-28 Dipharma Francis S.r.l. Process for the preparation of an antidepressant and the intermediates thereof
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
US10227317B2 (en) 2015-02-25 2019-03-12 Lupin Limited Process for the preparation of vortioxetine
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
WO2017013031A1 (en) 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
WO2017029377A1 (en) * 2015-08-19 2017-02-23 Amneal Pharmaceuticals Company Gmbh Process for preparation of vortioxetine hydrobromide
US20180303772A1 (en) * 2015-10-14 2018-10-25 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
CA3026728A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
BR112019000706A8 (pt) 2016-07-15 2022-12-06 Pasteur Institut Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
US20210284615A1 (en) * 2016-07-22 2021-09-16 Qingeng Li Vortioxetine analogue and use and preparation thereof
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
WO2018150344A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
WO2018154451A1 (en) * 2017-02-23 2018-08-30 Unichem Laboratories Ltd An improved process for preparation and purification of vortioxetine hydrobromide
PT3615518T (pt) * 2017-04-25 2022-02-14 H Lundbeck As Processo de fabrico da forma alfa da vortioxetina hbr
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
ES2976985T3 (es) 2018-06-20 2024-08-14 Vio Ag Pharmaceuticals S A Enfoque de activación C-H organo-pseudocatalítica de un recipiente para la preparación de vortioxetina y producto intermedio de vortioxetina
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
AU2021246973A1 (en) 2020-04-03 2022-11-03 H. Lundbeck A/S 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting
US12281088B2 (en) 2020-09-10 2025-04-22 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Process for the synthesis of vortioxetine
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151751B1 (enEXAMPLES) 1971-04-13 1973-11-19
CS151752B1 (enEXAMPLES) 1971-04-13 1973-11-19
CS151753B1 (enEXAMPLES) 1971-04-13 1973-11-19
CS151755B1 (enEXAMPLES) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198419A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
ES2004809A6 (es) * 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
EP0755923B1 (en) 1995-01-23 2005-05-04 Daiichi Suntory Pharma Co., Ltd. Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2681877A1 (en) * 1997-10-31 1999-05-14 Asubio Pharma Co., Ltd. Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
NZ515238A (en) 1999-04-02 2005-02-25 Icos Corp Inhibitors of LFA-1 binding to ICAMs and uses thereof
JP2003528810A (ja) 1999-08-04 2003-09-30 ミレニアム ファーマスーティカルズ インク メラノコルチン−４受容体結合化合物及びその使用方法
EP1220780A4 (en) * 1999-09-14 2004-03-24 Pharmacopeia Inc ARTICLE COMPRISING A DISPENSING HEAD COMPRISING MULTIPLE CHANNELS
EA006071B1 (ru) * 1999-12-30 2005-08-25 Х.Лундбекк А/С Замещенные производные фенилпиперазина, их получение и применение
JP2003519227A (ja) 1999-12-30 2003-06-17 ハー・ルンドベック・アクチエゼルスカベット 置換されたベンゼン誘導体の製造方法
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
US7291619B2 (en) * 2001-01-23 2007-11-06 Eli Lilly And Company Melanocortin receptor agonists
EP1363890A4 (en) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP1458689B1 (en) * 2001-12-20 2007-04-11 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
ES2309514T3 (es) * 2003-04-04 2008-12-16 H. Lundbeck A/S Derivados de 4-(2-fenilsufanil-fenil)-piperidina como inhibidores de la recaptacion de serotonina.
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
DK2044043T4 (da) * 2006-06-16 2021-04-12 H Lundbeck As 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazinhydrobromid som en forbindelse med kombineret serotoningenoptag, 5-ht3 og 5-ht1a-aktivitet til behandling af kognitiv svækkelse

Also Published As

Publication number Publication date
HUP0402313A2 (hu) 2005-02-28
AU2006215994A9 (en) 2006-10-05
US7148238B2 (en) 2006-12-12
PL368442A1 (pl) 2005-03-21
BR122012009534B1 (pt) 2018-02-27
CY1110064T1 (el) 2015-01-14
KR20060118020A (ko) 2006-11-17
UA93857C2 (uk) 2011-03-25
AU2002333220B2 (en) 2008-02-07
LTC1436271I2 (lt) 2016-09-12
US7683053B2 (en) 2010-03-23
PL209253B1 (pl) 2011-08-31
ES2298425T3 (es) 2008-05-16
ZA200401583B (en) 2005-05-25
AR066460A2 (es) 2009-08-19
EP1749818A2 (en) 2007-02-07
ES2298425T7 (es) 2022-06-27
MEP6508A (xx) 2010-02-10
LU92397I2 (fr) 2014-05-12
US8110567B2 (en) 2012-02-07
FR14C0033I1 (enEXAMPLES) 2014-06-13
PT1749818E (pt) 2009-10-06
RS27704A (en) 2006-10-27
MXPA04002959A (es) 2004-07-05
US10844029B2 (en) 2020-11-24
US20050014740A1 (en) 2005-01-20
CO5580746A2 (es) 2005-11-30
PL210551B1 (pl) 2012-02-29
BR122012023120B8 (pt) 2022-01-18
KR20070103515A (ko) 2007-10-23
CY2014022I1 (el) 2015-12-09
HUP0402313A3 (en) 2010-03-29
DE60233608D1 (de) 2009-10-15
EP1436271B3 (en) 2022-04-20
BRPI0212733B8 (pt) 2021-05-25
JP2007031447A (ja) 2007-02-08
US7138407B2 (en) 2006-11-21
AU2002333220A2 (en) 2003-04-14
HK1072600A1 (en) 2005-09-02
DK1436271T6 (da) 2022-06-27
AU2006215994B2 (en) 2008-11-13
DE60225162D1 (de) 2008-04-03
EA007537B1 (ru) 2006-10-27
NO20083446L (no) 2004-04-21
NZ531556A (en) 2005-12-23
RS52326B (en) 2012-12-31
JP3955614B2 (ja) 2007-08-08
NO2014011I2 (no) 2015-08-31
CY1107924T1 (el) 2013-09-04
SI1436271T1 (sl) 2008-06-30
AU2006215994A2 (en) 2006-10-05
EA007537B3 (ru) 2015-02-27
CA2462110A1 (en) 2003-04-10
AU2002333220C1 (en) 2023-10-05
US20060089368A1 (en) 2006-04-27
US20060084662A1 (en) 2006-04-20
HRP20040220A2 (en) 2005-02-28
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
RS52865B (en) 2013-12-31
CY2014022I2 (el) 2015-12-09
BR122012009534B8 (pt) 2019-01-29
KR100783346B1 (ko) 2007-12-07
EA011096B1 (ru) 2008-12-30
ATE441631T1 (de) 2009-09-15
KR20040047886A (ko) 2004-06-05
EP1749818A3 (en) 2008-04-02
JP3896116B2 (ja) 2007-03-22
MY140950A (en) 2010-02-12
US20070060574A1 (en) 2007-03-15
IS7164A (is) 2004-02-26
US9090575B2 (en) 2015-07-28
UA81749C2 (uk) 2008-02-11
JP2007051149A (ja) 2007-03-01
HU230189B1 (hu) 2015-09-28
US20160137620A1 (en) 2016-05-19
US9708280B2 (en) 2017-07-18
CN1319958C (zh) 2007-06-06
BR0212733B1 (pt) 2014-05-13
RS20120158A3 (en) 2013-10-31
CA2462110E (en) 2003-04-10
EA200400498A1 (ru) 2004-08-26
NO20041628L (no) 2004-04-21
CN1561336A (zh) 2005-01-05
NO332355B1 (no) 2012-09-03
RS20120158A2 (en) 2012-10-31
ES2328725T3 (es) 2009-11-17
EG25095A (en) 2011-08-17
BR122012023120B1 (pt) 2017-03-21
IS2578B (is) 2010-02-15
IL160655A0 (en) 2004-07-25
PT1436271E (pt) 2008-04-10
KR100842702B1 (ko) 2008-07-01
DK1749818T3 (da) 2009-10-12
US20180127389A1 (en) 2018-05-10
NL300652I1 (enEXAMPLES) 2016-01-18
US8476279B2 (en) 2013-07-02
US20140163043A1 (en) 2014-06-12
IS8806A (is) 2009-03-10
AR036659A1 (es) 2004-09-22
US20120302553A1 (en) 2012-11-29
FR14C0033I2 (fr) 2014-11-14
EA200601269A1 (ru) 2007-02-27
EP1436271A1 (en) 2004-07-14
EP1749818B1 (en) 2009-09-02
KR100770194B1 (ko) 2007-10-25
US20210276966A1 (en) 2021-09-09
NO326443B1 (no) 2008-12-08
US7144884B2 (en) 2006-12-05
WO2003029232A1 (en) 2003-04-10
NL300652I2 (enEXAMPLES) 2016-01-18
US20110009423A1 (en) 2011-01-13
BE2014C036I2 (enEXAMPLES) 2021-11-22
JP3955613B2 (ja) 2007-08-08
EP1436271B1 (en) 2008-02-20
IS2732B (is) 2011-04-15
ME00039B (me) 2010-06-10
HUS1400012I1 (hu) 2020-12-28
HU228956B1 (en) 2013-07-29
CA2462110C (en) 2010-05-11
DK1436271T3 (da) 2008-06-09
DE60225162T2 (de) 2009-02-12
JP2005505585A (ja) 2005-02-24
BR0212733A (pt) 2004-11-16
NO2014011I1 (no) 2014-05-13
AU2006215994A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
ATE386730T1 (de) Phenylpiperazinderivate als serotonin wiederaufnahmehemmer
ATE370137T1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
ATE299142T1 (de) Phenylpiperazin-derivate als inhibitoren der serotonin-wiederaufnahme
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
IS8439A (is) Nýjar kínólín afleiður
NO20041293D0 (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
NO20034308D0 (no) Nye tyrokinase-inhibitorer
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
NO20034970D0 (no) Nye arylheteroalkylaminderivater
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
IS8180A (is) Nýjar besímídasólafleiður
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
DE50303161D1 (de) Zentrierspanner
DE60328978D1 (de) Isochinolinderivate als mao-b inhibitoren
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
ATE281435T1 (de) Phenyl-heterocyclyl-ether-derivate als serotonin re-uptake inhibitoren
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
NO20035248D0 (no) Nye fenylalkyloksy-fenyl derivater
DE60328233D1 (de) Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1436271

Country of ref document: EP